Cargando…

Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis

Nausea and diarrhea are the most common adverse effects of nintedanib in patients with idiopathic pulmonary fibrosis (IPF). However, the clinical risk factors for these side effects remain unknown. In the present study, we investigated the characteristics of patients who developed gastrointestinal s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Motoyasu, Sasaki, Shinichi, Nakamura, Takahiro, Kurokawa, Kana, Yamada, Tomoko, Ochi, Yusuke, Ihara, Hiroaki, Takahashi, Fumiyuki, Takahashi, Kazuhisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700168/ https://www.ncbi.nlm.nih.gov/pubmed/31427707 http://dx.doi.org/10.1038/s41598-019-48593-4

Ejemplares similares

Author Correction: Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis
por: Kato, Motoyasu, et al.
Publicado: (2020)

Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting
por: Kato, Motoyasu, et al.
Publicado: (2021)

Prognostic differences among patients with idiopathic interstitial pneumonias with acute exacerbation of varying pathogenesis: a retrospective study
por: Kato, Motoyasu, et al.
Publicado: (2019)

Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world
por: Kato, Motoyasu, et al.
Publicado: (2023)

Pneumatosis intestinalis with free air in the abdominal cavity caused by nintedanib
por: Sakamoto, Naho, et al.
Publicado: (2023)

Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study
por: Nakamura, Kota, et al.
Publicado: (2017)

Management of skin sarcoidosis with minocycline monotherapy
por: Sasaki, Shinichi, et al.
Publicado: (2019)

Development of interstitial pneumonia during treatment with eribulin: a case report
por: Nakamura, Kota, et al.
Publicado: (2017)

Nintedanib ameliorates experimental pulmonary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation
por: Tsutsumi, Takeo, et al.
Publicado: (2019)

The synergetic effect of Imipenem-clarithromycin combination in the Mycobacteroides abscessus complex
por: Takei, Satomi, et al.
Publicado: (2020)

Tranilast Inhibits Pulmonary Fibrosis by Suppressing TGFβ/SMAD2 Pathway
por: Kato, Motoyasu, et al.
Publicado: (2020)

Development of diffuse alveolar damage after initiation of Nijutsuto
por: Kato, Motoyasu, et al.
Publicado: (2016)

Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis
por: Nasser, Mouhamad, et al.
Publicado: (2021)

Hermansky-Pudlak syndrome-associated pneumothorax with rapid progression of respiratory failure: a case report
por: Kato, Yukari, et al.
Publicado: (2020)

The synergetic effect of sitafloxacin–arbekacin combination in the Mycobacterium abscessus species
por: Watanabe, Junko, et al.
Publicado: (2023)

Gastric perforation related to concurrent use of nintedanib and ramucirumab
por: Takahashi, Saeko, et al.
Publicado: (2018)

Tocilizumab, a Proposed Therapy for the Cachexia of Interleukin6-Expressing Lung Cancer
por: Ando, Katsutoshi, et al.
Publicado: (2014)

Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases
por: Ito, Yoko, et al.
Publicado: (2019)

Nintedanib in advanced NSCLC: management of adverse events
por: Lemmens, Liesbeth
Publicado: (2016)

Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis
por: Fukunaga, Kentaro, et al.
Publicado: (2018)

Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib
por: Rahaghi, Franck, et al.
Publicado: (2021)

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
por: Wollin, Lutz, et al.
Publicado: (2015)

Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis
por: Tomioka, Hiromi, et al.
Publicado: (2017)

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
por: Yoon, Hee-Young, et al.
Publicado: (2018)

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis
por: Hajari Case, Amy, et al.
Publicado: (2017)

Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis
por: Nishiyama, Osamu, et al.
Publicado: (2021)

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2015)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
por: Rodríguez-Portal, José Antonio
Publicado: (2017)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Colitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
por: Oda, Keishi, et al.
Publicado: (2017)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis
por: Shimomura, Iwao, et al.
Publicado: (2018)

Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
por: Imai, Ryosuke, et al.
Publicado: (2020)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil
por: Pereira, Carlos Alberto de Castro, et al.
Publicado: (2019)

TWEAK enhances TGF-β-induced epithelial-mesenchymal transition in human bronchial epithelial cells
por: Itoigawa, Yukinari, et al.
Publicado: (2015)

Improvement in Subjective Symptoms and Tolerability in Response to Nintedanib Treatment in Elderly Patients with Idiopathic Pulmonary Fibrosis
por: Takeda, Takayuki, et al.
Publicado: (2020)

A successful treatment of rheumatoid arthritis-related interstitial pneumonia with nintedanib
por: Kakuwa, Tamaki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_chbvhkm3ei75c3vk7uije4pshc